Detalhe da pesquisa
1.
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.
Oncologist
; 29(4): 303-310, 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37995313
2.
An Integrated Care Approach to Improve Well-Being in Breast Cancer Patients.
Curr Oncol Rep
; 26(4): 346-358, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38400984
3.
Vasomotor symptoms and management of women undergoing treatment for breast cancer: literature review with focus on the therapeutic potential of cytoplasmic pollen extract.
Gynecol Endocrinol
; 39(1): 2162035, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36591791
4.
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial.
Int J Med Sci
; 18(10): 2245-2250, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33859534
5.
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence.
J Cell Physiol
; 235(11): 7900-7910, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31943171
6.
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
Int J Cancer
; 146(7): 1917-1929, 2020 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31330065
7.
Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study.
BMC Cancer
; 20(1): 232, 2020 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32188417
8.
Palliative electrochemotherapy in primary or recurrent vulvar cancer.
Int J Gynecol Cancer
; 30(7): 927-931, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32371425
9.
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.
J Cell Physiol
; 234(6): 7708-7717, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30536609
10.
Upfront HIPEC and bevacizumab-containing adjuvant chemotherapy in advanced epithelial ovarian cancer.
Int J Hyperthermia
; 35(1): 370-374, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30300042
11.
Characterization of a new BRCA1 rearrangement in an Italian woman with hereditary breast and ovarian cancer syndrome.
Breast Cancer Res Treat
; 164(2): 497-503, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28488140
12.
BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Am J Obstet Gynecol
; 217(3): 334.e1-334.e9, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28549976
13.
Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.
Eur J Clin Pharmacol
; 73(2): 157-164, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27864592
14.
Real-World Management of Trabectedin/Pegylated Liposomal Doxorubicin in Platinum-Sensitive Recurrent Ovarian Cancer Patients: A National Survey.
Int J Gynecol Cancer
; 27(6): 1141-1148, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28574933
15.
Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study.
Ann Surg Oncol
; 22 Suppl 3: S952-8, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26036187
16.
Corrigendum: Aromatase inhibitors: the journey from the state of the art to clinical open questions.
Front Oncol
; 14: 1369562, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38327748
17.
Preventing Bone Loss in Breast Cancer Patients: Designing a Personalized Clinical Pathway in a Large-Volume Research Hospital.
J Pers Med
; 14(4)2024 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38672998
18.
Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis.
Front Oncol
; 14: 1362641, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38595817
19.
Aromatase inhibitors: the journey from the state of the art to clinical open questions.
Front Oncol
; 13: 1249160, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38188305
20.
Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project.
Front Oncol
; 13: 1247270, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37954071